Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Positive Results Move Anemia Contender Enarodustat Towards First Filing

Executive Summary

Japanese firms unveil pivotal top-line results that pave way for first filing of novel anemia therapy within new class of agents, but competition is high and timings remain unclear.

You may also be interested in...



First Approval For AZ's Roxadustat With China Green Light

China is the first country to give the green light to roxadustat, AstraZeneca and FibroGen's first-in-class oral inhibitor of HIF-PHI, which could become standard of care to treat anemia in chronic kidney disease patients.

Akebia Holds Development Reins In Anemia While Otsuka Jumps On Vadadustat Sleigh

Co-development deal worth $265m in near-term cash will allow Akebia to tap into Otsuka's established kidney disease infrastructure, while holding the reins on key aspects of commercialization.

Coronavirus Update: Sotrovimab Filed For EUA In Japan

GSK could soon see an approval in Japan for its antibody therapy following a filing for emergency use, while South Korea looks to build its mRNA vaccine capabilities through a new consortium. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC125544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel